What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025Blood

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis linked hypomethylating agent failure and acute myeloid leukemia, indicating urgent need for novel therapies.

HMAF patients had a median overall survival of 8.7 months, with a significant portion progressing to acute myeloid leukemia.
TP53 mutations and cytopenia significantly predicted worse outcomes in patients post-HMA treatment.
Observational analysis across a cohort of 700 patients showed varying responses to treatment after HMA failure.
Stem cell transplantation improved survival outcomes compared to other therapies after hypomethylating agent failure.

Chien et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark